Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States
Cambridge, UK and New York, US, 24 September 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States. Tania is based at Artios’s new offices in New York City and is responsible for leading the company’s global partnering and business development strategy and execution, as the company advances its discovery programmes, including its Polymerase theta (Polθ) programme towards the market.
